Opinion - Shaping the future of biomarker research in breast cancer to ensure clinical relevance

被引:63
作者
Hinestrosa, M. Carolina
Dickersin, Kay
Klein, Pamela
Mayer, Musa
Noss, Karin
Slamon, Dennis
Sledge, George
Visco, Frances M.
机构
[1] Natl Breast Canc Coalit Fund, Washington, DC 20036 USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA
[3] Virginia Breast Canc Fdn, Richmond, VA 23230 USA
[4] Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Dept Med, Los Angeles, CA USA
[5] Indiana Univ, Med Ctr, Indianapolis, IN 46202 USA
关键词
D O I
10.1038/nrc2113
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Each year, over 200,000 people are diagnosed with breast cancer in the United States. Although the use of biomarkers has the potential to guide preventive interventions and improve survival and quality of life, there have been few successes and many disappointments. In November 2005, the National Breast Cancer Coalition Fund convened a conference aimed at developing a patient-centred, strategic approach to breast cancer biomarker research. The consumers, clinicians, researchers, industry representatives and US regulators who served on the consensus panel developed a set of principles and recommendations to guide the field and ensure that biomarker research results in clinically important applications.
引用
收藏
页码:309 / 315
页数:7
相关论文
共 21 条
[1]  
*ACS, 2007, CANC FACTS FIG 2007
[2]   Endorsement of the CONSORT statement by high impact medical journals: survey of instructions for authors [J].
Altman, DG .
BMJ-BRITISH MEDICAL JOURNAL, 2005, 330 (7499) :1056-1057
[3]   2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology [J].
Bast, RC ;
Ravdin, P ;
Hayes, DF ;
Bates, S ;
Fritsche, H ;
Jessup, JM ;
Kemeny, N ;
Locker, GY ;
Mennel, RG ;
Somerfield, MR .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1865-1878
[4]  
Bellman Philip, 2005, Perm J, V9, P27
[5]   Is this clinical trial fully registered? - A statement from the International Committee of Medical Journal Editors. [J].
De Angelis, CD ;
Drazen, JM ;
Frizelle, FA ;
Haug, C ;
Hoey, J ;
Horton, R ;
Kotzin, S ;
Laine, C ;
Marusic, A ;
Overbeke, AJPM ;
Schroeder, TV ;
Sox, HC ;
Van Der Weyden, MB .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (23) :2436-2438
[6]   Clinical trial registration - A statement from the International Committee of Medical Journal Editors [J].
DeAngelis, CD ;
Drazen, JM ;
Frizelle, FA ;
Haug, C ;
Hoey, J ;
Horton, R ;
Kotzin, S ;
Laine, C ;
Marusic, A ;
Overbeke, AJPM ;
Schroeder, TV ;
Sox, HC ;
Van der Weyden, MB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (11) :1363-1364
[7]   Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers [J].
Hayes, DF ;
Bast, RC ;
Desch, CE ;
Fritsche, H ;
Kemeny, NE ;
Jessup, JM ;
Locker, GY ;
MacDonald, JS ;
Mennel, RG ;
Norton, L ;
Ravdin, P ;
Taube, S ;
Winn, RJ .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (20) :1456-1466
[8]   Reporting recommendations for tumor marker prognostic studies (REMARK) [J].
McShane, LM ;
Altman, DG ;
Sauerbrei, W ;
Taube, SE ;
Gion, M ;
Clark, GM .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (16) :1180-1184
[9]   REporting recommendations for tumour MARKer prognostic studies (REMARK) [J].
McShane, LM ;
Altman, DG ;
Sauerbrei, W ;
Taube, SE ;
Gion, M ;
Clark, GM .
EUROPEAN JOURNAL OF CANCER, 2005, 41 (12) :1690-1696
[10]   REporting recommendations for tumour MARKer prognostic studies (REMARK) [J].
McShane L.M. ;
Altman D.G. ;
Sauerbrei W. ;
Taube S.E. ;
Gion M. ;
Clark G.M. .
British Journal of Cancer, 2005, 93 (4) :387-391